Jennifer Lois McKimm-Breschkin

List of Publications by Year
in descending order

Version: 2024-02-01

64 papers	5,337 citations	136740 32 h-index	118652 62 g-index
66 all docs	66 docs citations	66 times ranked	5896 citing authors

#	Article	IF	Citations
1	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment â€“ Meeting report from an isirv-WHO virtual conference. Antiviral Research, 2022, 197, 105227.	1.9	19
2	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Research, 2021, 194, 105158.	1.9	24
3	Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors. Antiviral Research, 2020, 182, 104895.	1.9	1
4	A clinical trial lacking a control group. International Journal of Infectious Diseases, 2019, 89, 189.	1.5	0
5	Influenza Virus Neuraminidase Structure and Functions. Frontiers in Microbiology, 2019, 10, 39.	1.5	280
6	Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant. Antiviral Research, 2019, 169, 104542.	1.9	5
7	Structure of an Influenza A virus N9 neuraminidase with a tetrabrachion-domain stalk. Acta Crystallographica Section F, Structural Biology Communications, 2019, 75, 89-97.	0.4	7
8	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro-N-acetylneuraminic Acid Derivatives. Journal of Medicinal Chemistry, 2018, 61, 1921-1933.	2.9	9
9	Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility. Antiviral Research, 2018, 153, 95-100.	1.9	10
10	The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virology Journal, 2015, 12, 67.	1.4	42
11	Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN). Antiviral Research, 2015, 123, 216-223.	1.9	15
12	Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation. Antiviral Research, 2015, 114, 62-66.	1.9	15
13	Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal. Antiviral Research, 2014, 108, 30-35.	1.9	4
14	Stereoselective synthesis and sialidase inhibition properties of KDO-based glycosyloxathiins. Arkivoc, 2014, 2014, 65-79.	0.3	1
15	Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. Journal of Antimicrobial Chemotherapy, 2013, 68, 2210-2221.	1.3	40
16	Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity. Science, 2013, 340, 71-75.	6.0	175
17	Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza and Other Respiratory Viruses, 2013, 7, 25-36.	1.5	291
18	I222 Neuraminidase Mutations Further Reduce Oseltamivir Susceptibility of Indonesian Clade 2.1 Highly Pathogenic Avian Influenza A(H5N1) Viruses. PLoS ONE, 2013, 8, e66105.	1.1	21

#	Article	IF	Citations
19	In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. Journal of Antimicrobial Chemotherapy, 2012, 67, 1874-1883.	1.3	27
20	Taking down the FLAG! How Insect Cell Expression Challenges an Established Tag-System. PLoS ONE, 2012, 7, e37779.	1.1	21
21	A Generic System for the Expression and Purification of Soluble and Stable Influenza Neuraminidase. PLoS ONE, 2011, 6, e16284.	1.1	41
22	Plaque Formation Assay for Human Parainfluenza Virus Type 1. Biological and Pharmaceutical Bulletin, 2011, 34, 996-1000.	0.6	9
23	Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors. Antiviral Research, 2011, 91, 20-22.	1.9	7
24	Real Time Enzyme Inhibition Assays Provide Insights into Differences in Binding of Neuraminidase Inhibitors to Wild Type and Mutant Influenza Viruses. PLoS ONE, 2011, 6, e23627.	1.1	35
25	Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses. Journal of Medicinal Chemistry, 2010, 53, 6421-6431.	2.9	75
26	Complexity in Influenza Virus Targeted Drug Design: Interaction with Human Sialidases. Journal of Medicinal Chemistry, 2010, 53, 2998-3002.	2.9	62
27	Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996â€“2007. Antiviral Therapy, 2009, 14, 751-762.	0.6	71
28	News About Influenza B Drug Resistance That Cannot Be Ignored. JAMA - Journal of the American Medical Association, 2007, 297, 1492-3.	3.8	16
29	ER Stress Triggers Apoptosis by Activating BH3-Only Protein Bim. Cell, 2007, 129, 1337-1349.	13.5	1,235
30	Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir. Emerging Infectious Diseases, 2007, 13, 1354-1357.	2.0	65
31	Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir. Emerging Infectious Diseases, 2007, 13, 1354-1357.	2.0	108
32	Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. Antimicrobial Agents and Chemotherapy, 2006, 50, 2395-2402.	1.4	333
33	Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 947-952.	2.5	36
34	Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. Journal of Antimicrobial Chemotherapy, 2006, 58, 723-732.	1.3	94
35	Neuraminidase Inhibitor-Resistant and -Sensitive Influenza B Viruses Isolated from an Untreated Human Patient. Antimicrobial Agents and Chemotherapy, 2006, 50, 1872-1874.	1.4	66
36	Dimeric Zanamivir Conjugates with Various Linking Groups Are Potent, Long-Lasting Inhibitors of Influenza Neuraminidase Including H5N1 Avian Influenza. Journal of Medicinal Chemistry, 2005, 48, 2964-2971.	2.9	82

#	Article	IF	Citations
37	Management of Influenza Virus Infections with Neuraminidase Inhibitors. Treatments in Respiratory Medicine, 2005, 4, 107-116.	1.4	62
38	A simplified plaque assay for respiratory syncytial virusâ€"direct visualization of plaques without immunostaining. Journal of Virological Methods, 2004, 120, 113-117.	1.0	96
39	Inhibition of Parainfluenza Virus Type 3 and Newcastle Disease Virus Hemagglutinin-Neuraminidase Receptor Binding: Effect of Receptor Avidity and Steric Hindrance at the Inhibitor Binding Sites. Journal of Virology, 2004, 78, 13911-13919.	1.5	51
40	Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Research, 2004, 103, 205-211.	1.1	26
41	Structure of the Haemagglutinin-neuraminidase from Human Parainfluenza Virus Type III. Journal of Molecular Biology, 2004, 335, 1343-1357.	2.0	200
42	Tethered Neuraminidase Inhibitors That Bind an Influenza Virus: A First Step Towards a Diagnostic Method for Influenza. Angewandte Chemie - International Edition, 2003, 42, 3118-3121.	7.2	22
43	Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opinion on Pharmacotherapy, 2002, 3, 103-112.	0.9	37
44	Mechanisms of resistance of influenza virus to neuraminidase inhibitors. International Congress Series, 2001, 1219, 855-861.	0.2	6
45	Antiviral Activity and Structural Characteristics of the Nonglycosylated Central Subdomain of Human Respiratory Syncytial Virus Attachment (G) Glycoprotein. Journal of Biological Chemistry, 2001, 276, 38988-38994.	1.6	22
46	Biochemical Methods for the Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en. , 2000, 24, 367-374.		4
47	Virological Methods for the Generation and Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en. , 2000, 24, 375-382.		3
48	The Interaction of Neuraminidase and Hemagglutinin Mutations in Influenza Virus in Resistance to 4-Guanidino-Neu5Ac2en. Virology, 1998, 246, 95-103.	1.1	101
49	Substrate, Inhibitor, or Antibody Stabilizes the Glu 119 Gly Mutant Influenza Virus Neuraminidase. Virology, 1998, 247, 14-21.	1.1	15
50	Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure, 1998, 6, 735-746.	1.6	210
51	Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors. Journal of Virology, 1998, 72, 2456-2462.	1.5	175
52	Use of oligonucleotide probes for selecting potential high-yielding influenza reassortants. Journal of Virological Methods, 1997, 68, 139-145.	1.0	2
53	Changes in the NS gene of neurovirulent strains of influenza affect splicing. Virus Genes, 1995, 10, 91-94.	0.7	7
54	Generation and Characterization of an Influenza Virus Neuraminidase Variant with Decreased Sensitivity to the Neuraminidase-Specific Inhibitor 4-Guanidino-Neu5Ac2en. Virology, 1995, 214, 475-484.	1.1	155

#	Article	IF	Citations
55	The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure, 1994, 2, 733-746.	1.6	157
56	Complete nucleotide sequence of the non-structural gene of the human influenza virus strain A/WS/33. Nucleic Acids Research, 1993, 21, 2257-2257.	6.5	4
57	Rapid treatment of whole cells and RNA viruses for analysis of RNA by slot blot hybridization. Virus Research, 1992, 22, 199-206.	1.1	2
58	Expression of influenza neuraminidase in baculovirus-infected cells. Virus Research, 1992, 26, 127-139.	1.1	14
59	The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins: Structure, Function and Bioinformatics, 1992, 14, 327-332.	1.5	399
60	The use of tetramethylbenzidine for solid phase immunoassays. Journal of Immunological Methods, 1990, 135, 277-280.	0.6	67
61	P Cell Stimulating Factor Release: A Useful Assay of T Cell Activation in vitro. International Archives of Allergy and Immunology, 1986, 79, 169-177.	0.9	10
62	Pertussigen enhances antigen-driven interferon-Î³ production by sensitized lymphoid cells. Cellular Immunology, 1986, 97, 238-247.	1.4	25
63	Preparation of T cell growth factor free from interferon and factors stimulating hemopoietic cells and mast cells. Journal of Immunological Methods, 1982, 51, 311-322.	0.6	13
64	Interferon Induction by Measles Virus. Intervirology, 1981, 16, 250-259.	1.2	2